STOCK TITAN

Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
AI
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) launches Patholytix Foresight, an AI decision support tool in collaboration with Deciphex. The tool enhances toxicologic pathology assessment, accelerates primary evaluation, and peer review in drug discovery. Patholytix Foresight streamlines workflows, improves efficiency, consistency, and accuracy in analyzing histopathology data.
Positive
  • None.
Negative
  • None.

The launch of Patholytix Foresight represents a technological advancement in toxicologic pathology, an area critical for evaluating the safety of new pharmaceutical compounds. The integration of AI into pathology practices promises to enhance the efficiency and accuracy of drug safety assessments, which is a key step in the drug development process. By accelerating the primary evaluation and peer review, this tool could potentially shorten the time to market for new drugs.

For stakeholders, including investors in Charles River Laboratories and the biopharmaceutical sector, this innovation could translate into reduced costs and faster turnaround times for safety assessments. However, it's important to monitor the adoption rate of this new technology within the industry and its impact on Charles River's revenue streams. The long-term implications could include a shift in industry standards towards AI-augmented pathology evaluations, potentially raising the bar for competitors.

With the increasing demand for rapid drug development cycles, tools like Patholytix Foresight are positioned to meet a growing market need. The collaboration between Charles River Laboratories and Deciphex taps into the digital transformation trend within the pharmaceutical industry. From a market perspective, the ability to offer enhanced decision-making capabilities and faster assessments could provide Charles River with a competitive edge.

As the pharmaceutical industry continues to focus on efficiency and data-driven decision-making, the market for such AI-driven tools is likely to expand. Companies that are early adopters of this technology may gain significant advantages, including improved success rates in drug trials and enhanced regulatory compliance. However, it is essential to consider the challenges of integrating new technologies into established workflows and the potential resistance from traditionalists within the field.

The strategic implications of Patholytix Foresight for the healthcare industry involve not only the acceleration of drug development but also the potential for improved patient outcomes. By enabling more accurate toxicological assessments, the likelihood of identifying adverse effects early in the drug development process increases, which is important for patient safety.

Adoption of AI in non-clinical settings also sets a precedent for its broader use in clinical diagnostics and personalized medicine. The success of Patholytix Foresight could encourage further investments in AI applications within healthcare, driving innovation and potentially leading to a new era of digital pathology. It will be important to track how this technology influences regulatory policies and standards for AI in healthcare, as well as its acceptance by healthcare professionals.

Powered by digital pathology and AI algorithms, Patholytix Foresight drives speed and quality in toxicologic pathology practices

WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI. By combining Deciphex’s unique digital pathology solutions with Charles River’s robust non-clinical pathology programs, clients of both organizations will have access to the technology-driven capabilities to accelerate primary evaluation and peer review in toxicologic pathology assessment, enhancing decision-making in drug discovery and safety assessment.

In experimental and toxicologic pathology in particular, traditional light microscopic pathology methods can fall short of maintaining consistency and efficiency in analyzing histopathology data. By augmenting evaluations with decision support technology, toxicologic pathologists have access to simple, visual tools to facilitate efficiency, consistency, and accuracy in their work.

Developed through a research collaboration between Charles River and Deciphex, Patholytix Foresight incorporates organ-based lesion classifiers created from an extensive data warehouse. Built on Patholytix 4.0, Deciphex's flagship non-clinical workflow, the tool integrates these AI classifiers with Whole Slide Images (WSI) to enhance and accelerate a pathologist’s decision-making by streamlining workflows for identifying critical features in specific tissues.

Approved Quotes

  • “AI-powered solutions are accelerating the pace and efficiency of drug development, and the launch of Patholytix Foresight marks a significant milestone in our collaborative efforts to enhance the digital transformation of toxicological pathology.” – Professor Julie Frearson, PhD, Corporate Senior Vice President, Chief Scientific Officer, Charles River
  • “In collaboration with Charles River Laboratories, we look forward to bringing Patholytix Foresight to the forefront of digital pathology, empowering pathologists worldwide with cutting-edge AI technology for more efficient and accurate toxicological assessments. This advance is part of our collective vision to enable AI-empowered and regulated digital primary review of safety studies.” – Pierre Moulin, MD, PhD, MBA, Chief Scientific Officer, Deciphex

About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Deciphex
Deciphex is a pioneering company at the forefront of the digital transformation of pathology. By networking with global pathologists and leveraging AI-driven solutions, Deciphex accelerates certainty in pathology reporting, ultimately enhancing patient care and advancing drug development. With a diverse and experienced team and cutting-edge platforms like Diagnexia and Patholytix, Deciphex is set to redefine the future of pathology. For more information, visit www.deciphex.com.

Investor Contact:

Todd Spencer

Corporate Vice President,

Investor Relations

781.222.6455

todd.spencer@crl.com

Media Contact:

Amy Cianciaruso

Corporate Vice President,

Chief Communications Officer

781.222.6168

amy.cianciaruso@crl.com

Source: Charles River Laboratories International, Inc.

FAQ

What is the name of the AI decision support tool launched by Charles River Laboratories International, Inc. in collaboration with Deciphex?

Patholytix Foresight.

What is the purpose of Patholytix Foresight in toxicologic pathology practices?

To enhance decision-making in drug discovery and safety assessment by improving efficiency, consistency, and accuracy in analyzing histopathology data.

Who developed Patholytix Foresight in collaboration with Charles River Laboratories International, Inc.?

Deciphex.

What technology is integrated into Patholytix Foresight to streamline workflows for identifying critical features in specific tissues?

AI classifiers and Whole Slide Images (WSI).

What is the goal of bringing Patholytix Foresight to the forefront of digital pathology according to Pierre Moulin, Chief Scientific Officer of Deciphex?

To empower pathologists worldwide with cutting-edge AI technology for more efficient and accurate toxicological assessments.

Charles River Laboratories International, Inc.

NYSE:CRL

CRL Rankings

CRL Latest News

CRL Stock Data

11.05B
50.74M
0.98%
103.03%
3.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WILMINGTON

About CRL

charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro